Recent Updates
Recently added Catalysts
JAZZ Positive Sentiment

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

Key Takeaway: Jazz Pharmaceuticals has announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Citi 2026 Biopharma Back to School Summit. Management will engage in fireside chats to discuss the company's developments. Audio webcasts of these events will be available on their website.
Price reaction · baseline $245.57 (2026-09-02 close) · hit after-hours · clean, no other JAZZ news in the window
day 0 close · peak
+0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Jazz Pharmaceuticals is actively engaging with investors.
  • Participation in multiple prominent healthcare conferences.
  • Focus on innovative therapeutics for rare diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
2.1%
average across 14 past catalysts
Lead asset
GWP42004
Phase 2 · Diabetes Mellitus, Type 2

Full Press Release Details

DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:
• Wells Fargo 21 st Annual Healthcare Conference on Wednesday, September 9, 2026, at 1:30 p.m. ET
• Citi 2026 Biopharma Back to School Summit on Thursday, September 10, 2026, at 10:40 a.m. ET
• Morgan Stanley 24 th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 12:20 p.m. ET
• Deutsche Bank Healthcare Summit on Wednesday, September 16, 2026, at 8:00 a.m. ET
Audio webcasts of the fireside chats will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Investors: [email protected] Ireland +353 1 634 7800 U.S. +1 650 496 2717

Media: [email protected] Ireland +353 1 637 2141 U.S. +1 215 867 4948

Frequently Asked Questions

Which conferences will Jazz Pharmaceuticals attend?

Jazz Pharmaceuticals will attend the Wells Fargo, Citi, Morgan Stanley, and Deutsche Bank conferences.

What is the purpose of these investor conferences?

The conferences aim to engage investors and discuss Jazz Pharmaceuticals' developments.

Where can I find the webcasts of the events?

Webcasts will be available in the Investors section of Jazz Pharmaceuticals' website.

What is Jazz Pharmaceuticals' focus?

The company focuses on developing life-changing medicines for rare diseases.

Last updated: Sep 2, 2026